Embecta

Embecta

Embecta was established in 2022 when Becton, Dickinson and Company separated its Diabetes Care business into an independent publicly traded company listed on Nasdaq under the ticker EMB. Devdatt Kurdikar, a former BD executive, was appointed CEO to run the carve-out from its headquarters in Parsippany, New Jersey, with an additional operational presence in Massachusetts. The spin-off transferred a portfolio of injection devices — including the BD Ultra-Fine needle and the BD Nano pen needle — to the new entity, making Embecta one of the largest pure-play diabetes device manufacturers at launch. The company's commercial engine rests on high-volume sales of insulin syringes and pen needles, products that generate recurring, non-discretionary revenue from an installed base of type 1 and type 2 diabetes patients. Embecta distributes to institutional buyers including hospitals, long-term care facilities, and retail pharmacies across North America, Europe, and Asia. Beyond disposables, the firm is actively developing a tubeless insulin patch pump — a form factor that competes with Insulet's Omnipod — representing its primary growth investment of retained earnings rather than external deployment into third-party assets (per the firm's investor communications, 2023). Embecta employs roughly 2,000 people across its manufacturing and commercial sites, with an estimated over 2,000 employees globally including operations in Ireland and China. In May 2024, the company received FDA clearance for its proprietary disposable insulin delivery system intended for people with type 2 diabetes, marking its most significant regulatory milestone since the spin-off. The clearance allows Embecta to transition from a pure disposables business toward a connected-device competitor, a pivot that CEO Kurdikar has publicly identified as the company's strategic north star. Embecta occupies a narrow structural lane: it is neither a family office nor a venture investor, but a publicly traded medical-technology firm whose "moat" is the massive installed base of BD injection hardware and the regulatory barriers that protect needle-and-syringe manufacturing from easy commoditization. The carve-out structure grants management autonomy over capital allocation — currently channeled into internal R&D and a quarterly dividend — without the conglomerate overhead that previously deprioritized diabetes devices inside BD.